Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012
Adverse anti-tuberculosis drug events and their management Source: Eur Respir Monogr 2018; 82: 205-227 Year: 2018
Adverse drug reactions in a pulmonary teaching hospital: Incidence, pattern, seriousness, and preventability Source: Annual Congress 2011 - New insights in management of interstitial and vascular lung diseases Year: 2011
Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice Source: Eur Respir J, 50 (5) 1702135; 10.1183/13993003.02135-2017 Year: 2017
Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice Source: Eur Respir J, 50 (2) 1700148; 10.1183/13993003.00148-2017 Year: 2017
Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice Source: Eur Respir J, 50 (5) 1701984; 10.1183/13993003.01984-2017 Year: 2017
Risk of serious adverse reactions during the treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012
What do we need in the clinic and what approach can clinicians take to improve the drug development pipeline? Source: ERS Research Seminar 2016 Year: 2016
Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Exercise: management of adverse events: discussion of clinical cases Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012
Accuracy in assessment of acute asthma needs improved to avoid potential adverse outcomes Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
An innovative risk score for prediction of asthma related adverse outcome Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Eur Respir J 2007; 30: Suppl. 51, 125s Year: 2007
Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis Source: Eur Respir J 2010; 36: 206-208 Year: 2010
Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation Source: Eur Respir J 2014; 44: 1412-1417 Year: 2014
Predicting outcomes and drug resistance with new standardised treatment Source: Eur Respir J 2011; 37: 974 Year: 2011
Clinical analysis of adverse reactions to second line anti TB drugs Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012
An evidence-based, point-of-care tool to guide completion of asthma action plans in practice Source: Eur Respir J, 49 (5) 1602238; 10.1183/13993003.02238-2016 Year: 2017
Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019
Improving GINA adoption by designing a mobile based clinical decision support system Source: International Congress 2018 – Variant forms of asthma Year: 2018